Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Biotechnology
Wait for pullback to $12.90. Weak momentum; also insider activity concern — blocks BUY_NOW at $15.59. Engine's entry $12.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: Lonza.
Aurinia Pharmaceuticals is a biopharmaceutical company commercializing LUPKYNIS (voclosporin), the first FDA-approved oral therapy for lupus nephritis, directly in the U.S. and through an Otsuka collaboration in Europe, Japan, the U.K., and Switzerland. 2025 net product sales... Read more
Wait for pullback to $12.90. Weak momentum; also insider activity concern — blocks BUY_NOW at $15.59. Engine's entry $12.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: Lonza. Chart setup: RSI 53 mid-range, Bollinger mid-band. Fundamentals strong but target reached (-5.3% upside). Wait for pullback. Score 7.0/10, high confidence.
Passes 5/8 gates (no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
Recent Developments — Aurinia Pharmaceuticals Inc
Latest news
- Aurinia earnings on deck: Can new leadership sustain growth? By Investing.com - Investing.com Australia — Investing.com Australia neutral
- Tudor Investment Corp ET AL Buys Shares of 65,964 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat — MarketBeat positive
- Aurinia Pharmaceuticals Inc - Common Shares (NQ: AUPH - FinancialContent — FinancialContent neutral
- Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc - AD HOC NEWS — AD HOC NEWS positive
- AUPH (Aurinia) beats Q4 2025 EPS estimates by 17.6 percent, yet shares dip 1 percent in today’s session. - Collaborative — Newser positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductLUPKYNIS10-K Item 1A: 'The success of our business is substantially dependent on our ability to successfully commercialize LUPKYNIS, our sole approved product.'
- HIGHSupplierLonza10-K Item 1: 'Voclosporin requires a specialized drug substance manufacturing process and is manufactured by Lonza, our sole supplier for drug substance.'
- HIGHSupplierCatalent10-K Item 1: 'Catalent Pharma Solutions ("Catalent") is currently the sole supplier for the preparation of our voclosporin capsules.'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMKevin Tang, Chair of Aurinia's Board since 2024, appointed CEO and principal executive officer effective March 23, 2026. No disagreement with Company operations cited. Tang is founder of Tang Capital Management.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $12.90. Weak momentum; also insider activity concern — blocks BUY_NOW at $15.59. Engine's entry $12.90 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: Lonza. Chart setup: RSI 53 mid-range, Bollinger mid-band. Fundamentals strong but target reached (-5.3% upside). Wait for pullback. Target $16.54 (+6.1%), stop $11.64 (−33.9%), Setup A.R:R 1.6:1. Score 7.0/10, high confidence.
Take-profit target: $16.54 (+10.4% upside). Target $16.54 (+6.1%), stop $11.64 (−33.9%), Setup A.R:R 1.6:1. Stop-loss: $11.64.
Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: Lonza; Cyclical risk: PE expanding 1.9x (earnings normalizing).
Aurinia Pharmaceuticals Inc trades at a P/E of 7.2 (forward 13.9). TrendMatrix value score: 7.2/10. Verdict: Buy (Wait for Entry).
13 analysts cover AUPH with a consensus score of 3.9/5. Average price target: $17.
What does Aurinia Pharmaceuticals Inc do?Aurinia Pharmaceuticals is a biopharmaceutical company commercializing LUPKYNIS (voclosporin), the first FDA-approved...
Aurinia Pharmaceuticals is a biopharmaceutical company commercializing LUPKYNIS (voclosporin), the first FDA-approved oral therapy for lupus nephritis, directly in the U.S. and through an Otsuka collaboration in Europe, Japan, the U.K., and Switzerland. 2025 net product sales were $271.3 million, up 25% year-over-year. The company is also developing aritinercept, a dual BAFF/APRIL inhibitor for autoimmune diseases, in early clinical stages.